Divi's Laboratories — Q2 FY25
Divis Labs reported a strong Q2 FY25 with PAT surging 46.6% YoY to INR 510 Cr, driven by robust custom synthesis demand and operational efficiencies.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY25
Double-digit revenue growth expected for FY25
Management reiterated confidence in achieving double-digit growth for the full year, driven by both generics and custom synthesis.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1